| 1. |
|
|
| 2. |
|
|
| 3. |
- Sandström, Per, et al.
(författare)
-
Idiotypic-anti-idiotypic antibody interactions in experimental radioimmunotargeting.
- 1999
-
Ingår i: Clinical Cancer Research. - 1078-0432 .- 1557-3265. ; 5:10 Suppl, s. 3073s-3078s
-
Tidskriftsartikel (refereegranskat)abstract
- Idiotypic-anti-idiotypic antibody interactions can be used in vivo to regulate the serum levels of specific radiolabeled antibodies. Anti-idiotypic antibodies can also be used as clearing agents for radiolabeled antibodies in radioimmunolocalization and radioimmunotherapy. The present study describes the immunochemical interactions between the monoclonal idiotype (H7) and three generated monoclonal anti-idiotypic antibodies (alphaH7:1, alphaH7:35, and alphaH7:38). An unexpected variability in complex formation could be demonstrated in vitro, revealing three different stable complex patterns, i.e., low molecular weight 1:1 complexes, ladder formation with oligomeric, consecutively added constituents, and large linear polymeric complexes of high molecular weight. Within 24 h, the anti-idiotypes were able to cause a significant decrease in total body radioactivity, and the antibody generating a ladder formation (alphaH7:38) was found to be the most efficient at removing radiolabeled idiotypes from the circulation. It is concluded that monoclonal anti-idiotypic antibodies may be valuable tools in improving radioimmunolocalization and radioimmunotargeting.
|
|
| 4. |
- Ullén, Anders, et al.
(författare)
-
Dosimetry of fractionated administration of 125I-labeled antibody at experimental radioimmunotargeting.
- 1997
-
Ingår i: Cancer. - 0008-543X .- 1097-0142. ; 80:12 Suppl, s. 2510-2518
-
Tidskriftsartikel (refereegranskat)abstract
- In this antigen target system, a single injection of a large amount of antibody was found to be more efficient than the same antibody dose subdivided into three or ten fractions. It was concluded that not only the radioactivity but also the amount of antibody per fraction should be considered when determining optimal fractionated radioimmunotherapy.
|
|
